CD5 knockout CAR-T exhibited efficacy in several ... Cellular Immunotherapies at Perelman School of Medicine — helped pioneer tisagenlecleucel (Kymriah, Novartis), the first FDA-approved CAR ...

The CD5 protein is highly expressed on cancerous T cells in T-cell lymphoma and T-cell acute lymphoblastic leukemia, rare blood cancers that do not have effective immunotherapy treatment options.

but their anti-CD5 approach could offer an opportunity to intervene earlier—at the point of CAR-T activation, noted CAR-T pioneer and co-author of the current study, Carl June, M.D., professor ...

The CD5 protein is highly expressed on cancerous T cells in T-cell lymphoma and T-cell acute lymphoblastic leukemia, rare blood cancers that do not have effective immunotherapy treatment options.

The data are highlighted in a poster titled, “CD5 knockout enhances the potency of multiplex base-edited allogeneic anti-CD5 CAR T-cell therapy for the treatment of T-cell malignancies,” at ...

CD5 immunohistochemistry (IHC) was performed on 404 DLBCLs to identify CD5 IHC+ and CD5 IHC– cases, which were subsequently characterized at the molecular level through mutational and transcriptional ...

The CD5 protein is highly expressed on cancerous T cells in T-cell lymphoma and T-cell acute lymphoblastic leukemia, rare blood cancers that do not have effective immunotherapy treatment options.

The study, published today in Science Immunology, suggests that knocking out CD5 could be a prime technique. Illuminating the protein’s previously murky role, the researchers found that it works ...